Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000926617-14-000033
Filing Date
2014-05-15
Accepted
2014-05-15 16:01:04
Documents
12
Period of Report
2014-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q c617-20140331x10q.htm 10-Q 594412
2 EX-10.1 c617-20140331ex10172e78f.htm EX-10.1 60842
3 EX-31.1 c617-20140331ex3118ec1ef.htm EX-31.1 16282
4 EX-31.2 c617-20140331ex312ff5bdd.htm EX-31.2 16451
5 EX-32.1 c617-20140331ex32196c6df.htm EX-32.1 13710
6 GRAPHIC c617-20140331x10qg1.jpg GRAPHIC 18865
  Complete submission text file 0000926617-14-000033.txt   2026964

Data Files

Seq Description Document Type Size
7 EX-101.INS c617-20140331.xml EX-101.INS 135164
8 EX-101.SCH c617-20140331.xsd EX-101.SCH 17776
9 EX-101.CAL c617-20140331_cal.xml EX-101.CAL 25533
10 EX-101.DEF c617-20140331_def.xml EX-101.DEF 40025
11 EX-101.LAB c617-20140331_lab.xml EX-101.LAB 141695
12 EX-101.PRE c617-20140331_pre.xml EX-101.PRE 112555
Mailing Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738
Business Address 12117 BEE CAVES ROAD BUILDING THREE SUITE 100 AUSTIN TX 78738 512-519-0400
VERMILLION, INC. (Filer) CIK: 0000926617 (see all company filings)

EIN.: 330595156 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-34810 | Film No.: 14847018
SIC: 2835 In Vitro & In Vivo Diagnostic Substances